Quinidine, a class I antiarrhythmic agent with blocking property of transient outward current, is a possible candidate for the suppression of
ventricular fibrillation in patients with
Brugada syndrome; although there is a concern that its ability to these effects may be proarrhythmic. Therefore, we evaluated the effect of
quinidine sulfate on ST-segment elevation in
Brugada syndrome. In 8 patients with
Brugada syndrome, the magnitude of ST-elevation at the J-point (ST(J)), and the ST-segment configuration in leads V1-V3, were compared before and on day 2 after the initiation of
quinidine administration. In 3 patients,
quinidine attenuated ST(J) by > or = 0.1 mV. Of these 3 patients, ST-segment elevation was normalized in 2 patients, while the ST-segment configuration was unchanged in another. In another 3 patients,
quinidine augmented ST(J) by > or = 0.1 mV without any change of ST-segment configuration, and the augmentation was returned to baseline after the discontinuation of
quinidine.
Quinidine exhibited no effect on the ST-segment in the remaining 2 patients. The favorable effects of
quinidine on the ST-segment tended to be more pronounced in patients with prominent ST-elevation at baseline. In 1 patient,
quinidine was effective in eliminating both ST-segment elevation and repetitive
tachyarrhythmia episodes. In conclusion, the effects of
quinidine on ST-segment elevation were variable.
Quinidine may potentially augment the ST-segment elevation in some patients with
Brugada syndrome.